Tiba Biotech
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Tiba Biotech firmographics
Firmographics- Name
- Tiba Biotech
- Legal name
- Tiba Biotech LLC
- Website
- https://tiba.bio
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Tiba Biotech industry classification
Industry- Product category
- RNA Therapeutics and Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
Keywords
Where Tiba Biotech is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Tiba Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Government Grants and Contracts: Primary revenue source through NIH SBIR grants, BARDA contracts, and government agency partnerships. Non-dilutive funding for vaccine and therapeutic development.
- Strategic Partnership Agreements: Multi-year agreements with government bodies (e.g., NSW Australia five-year, multi-million US dollar agreement) for development of vaccines against emergency animal diseases.
- Licensing Royalties (Future): Potential future licensing of RNABL platform technology and vaccine candidates to pharmaceutical partners for clinical development and commercialization.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Tiba Biotech product offering
Product offeringCore offering
Tiba Biotech develops a proprietary biodegradable dendrimer nanoparticle delivery platform (RNABL) and a computational RNA design platform to create next-generation RNA vaccines and therapeutics for human and animal health. The company is pre-clinical and generates revenue through government grants and research partnerships rather than product sales, with a pipeline spanning pandemic influenza, betacoronaviruses, livestock diseases, and cancer immunotherapy.
Product overview
Tiba Biotech is a preclinical-stage biopharmaceutical company developing next-generation RNA medicines based on two core proprietary platforms: the RNABL™ dendrimer nanoparticle delivery platform and a computational RNA design platform. The company focuses on vaccine and therapeutic applications for human and animal health. Their portfolio includes vaccine candidates for infectious diseases (influenza, COVID-19, Foot-and-Mouth Disease, Japanese Encephalitis) and cancer immunotherapies, as well as RNAi-based therapeutics. The RNABL™ platform enables delivery of large RNA payloads with reduced reactogenicity and relaxed cold-chain requirements compared to traditional lipid nanoparticles. The RNA design platform employs computational and combinatoric approaches for rapid candidate development.
Differentiator
Problem solved
Functional benefit
Brands
- RNABL: Proprietary fully biodegradable nanoparticle delivery platform for RNA medicines. Enables safer delivery of nucleic acids with reduced side effects compared to traditional lipid nanoparticles (LNPs).
- RNABL Nanoparticles
Products and services
- RNABL Delivery Platform A proprietary fully synthetic biodegradable dendrimer nanoparticle delivery platform for RNA medicines, enabling delivery of large nucleic acid payloads with reduced side effects compared to traditional lipid nanoparticles (LNPs), relaxed cold-chain requirements, and superior safety. Used by Tiba's vaccine and therapeutic development programs and offered as the underlying technology platform for partnered development.
- RNA Design Platform
Quantifiable outcome
- Full protection in cattle challenge study with FMD vaccine - no viral shedding or adverse effects in all vaccinated animals
- +3 more outcomes
Companies that use Tiba Biotech
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Tiba Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Tiba Biotech partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and minor.
- Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) at The Pirbright InstitutecoreMulti-year collaboration to accelerate development of RNA vaccines for livestock diseases. Supported by Gates Foundation, UK FCDO, and BBSRC. Initial focus on molecular characterization of FMD vaccine candidate that showed complete protection in cattle.
- Friedrich Loeffler Institute (Germany)minorConducted FMD vaccine challenge study in cattle demonstrating full protection. All vaccinated animals showed no viral shedding or adverse effects.
- Biomedical Advanced Research and Development Authority (BARDA)coreBARDA awarded $749,999 FASTx contract to develop RNAi-based therapeutic for H1N1 influenza targeting viral nucleoprotein via RNABL platform. This extends Tiba's platform beyond vaccines into therapeutics. Tiba also accepted into Blue Knight program with JLABS.
- UNSW RNA InstituteminorManufactured BDV vaccine pilot in Sydney as part of NSW RNA manufacturing capability development. Contributing to establishing domestic RNA manufacturing infrastructure in Australia.
- Johnson & Johnson Innovation - JLABSminorThrough Blue Knight program, Tiba becomes virtual company within JLABS incubator with access to global network of life science innovation ecosystems and resources to advance healthcare solutions.
- Coalition for Epidemic Preparedness Innovations (CEPI)coreCEPI provided US$2 million to evaluate Tiba's RNABL platform and develop Japanese Encephalitis Virus vaccine candidate. Part of CEPI's $3.5 billion DiseaseX initiative aiming to compress vaccine development to 100 days. Option to extend to vaccine libraries against pandemic threats.
- NIH/NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs)coreExtended collaboration with academic partners (University of Minnesota, Emory University) to study level and duration of protection of Tiba's next-generation RNA vaccines. Part of NIAID's seven-year program with up to $51M in potential funding focused on universal influenza vaccine development.
- NSW Department of Primary Industries and Regional Development (DPIRD)coreFive-year, multi-million US dollar agreement to develop next-generation mRNA vaccines against emergency animal diseases (FMD, LSD). Part of broader Australian Federal/State initiative with additional support from Queensland, Australian Federal Dept. of Agriculture, and Meat & Livestock Australia.
- Elizabeth Macarthur Agricultural Institute (EMAI)minorNSW government research institute collaborating on establishing immune response, demonstrating animal safety, and optimizing formulation and dose for livestock vaccines.
- Canadian Food Inspection Agency (CFIA)minorPartnered on identifying protective antigens for livestock vaccines and contributing to immune response characterization for LSD and FMD vaccines.
- Australian Centre for Disease PreparednessminorGovernment research facility involved in the international collaboration for emergency animal disease vaccine development.
- Tufts University Cummings School of Veterinary MedicineminorCollaboration to develop next-generation vaccines against emerging tick-borne diseases, specifically Powassan virus. NIAID SBIR Phase I grant supporting early development of RNA vaccine strategy.
- Icahn School of Medicine at Mount Sinai (Prof. Florian Krammer)minorCollaboration on universal influenza vaccine using engineered hemagglutinin antigens administered in prime/boost regimen. Prof. Krammer's laboratory technology adapted to Tiba's RNA platform for improved manufacturability and speed of deployment.
- University of MinnesotaminorResearch collaboration on nasal delivery of RNABL nanoparticles and universal influenza vaccine development. Dr. David Masopust led study published in Science Immunology.
- King Abdullah University of Science and Technology (KAUST)minor$2.5M Near Term Grand Challenge to advance pan-betacoronavirus vaccine (SARS-CoV-2 and MERS-CoV). Tiba provides mRNA prime; KAUST develops protein boost for heterologous prime-boost approach targeting MENA regions.
- Carnegie Mellon UniversityminorCollaboration with Prof. Burak Ozdoganlar on 3D printed microneedle patch for intradermal mRNA vaccine delivery. Grant funded through CARES Act for painless, self-administering vaccine delivery.
- University of Pittsburgh Center for Vaccine ResearchminorCollaboration on novel COVID-19 mRNA vaccine using synthetic RNA in dendrimer nanoparticles. Led by Dr. William Klimstra with existing NIH grant converted to coronavirus work during pandemic.
- United States Army Medical Research Institute of Infectious Diseases (USAMRIID)minorEarly collaboration focused on pandemic preparedness and rapid response vaccine development. USAMRIID received Zika virus vaccine candidate from MIT/Whitehead in 2017.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Tiba Biotech competitors and assessment
Company assessmentBroad incumbents
- Moderna: Commercial-stage leader in mRNA vaccines and therapeutics with approved COVID-19 vaccine and broad pipeline. Most comparable as a direct competitor in mRNA vaccine technology, though at vastly larger scale and with an LNP-based delivery platform.
- BioNTech: Commercial mRNA company partnered with Pfizer on COVID-19 vaccine, with oncology and infectious disease pipeline. Direct competitor in mRNA vaccines/therapeutics using LNP delivery; relevant for benchmarking commercialization pathways.
Direct peers
- CureVac: Clinical-to-commercial mRNA company developing prophylactic vaccines and therapeutics using proprietary RNA technology. Comparable as an mRNA platform peer targeting infectious diseases and oncology, though still building commercial track record.
- Arcturus Therapeutics: Clinical-stage mRNA/saRNA company with proprietary lipid-mediated delivery and self-amplifying RNA technology. Most comparable peer — similar stage, similar platform approach, and overlapping indications including infectious disease vaccines.
- Translate Bio (acquired by Sanofi): Was a clinical-stage mRNA therapeutics company acquired by Sanofi in 2021 for ~$3.2B. Directly comparable as an mRNA platform developer targeting vaccines and protein replacement via proprietary delivery technology.
- Replicate Bioscience: Clinical-stage biotech developing self-amplifying RNA (saRNA) therapeutics for oncology and infectious disease. Highly comparable given shared saRNA payload approach and overlapping vaccine/therapeutic indications.
Others
- Acuitas Therapeutics: LNP delivery technology provider whose ionizable lipids underpin Moderna's and BioNTech/Pfizer's COVID vaccines. Highly relevant as the dominant incumbent delivery platform that Tiba's dendrimer technology is positioning against.
- Genevant Sciences: LNP-based nucleic acid delivery technology company with lipid nanoparticle IP licensed broadly across the mRNA industry. Comparable as an alternative delivery platform peer whose IP footprint defines the LNP licensing landscape Tiba is seeking to circumvent.
Emerging players
- Strand Therapeutics: Pre-clinical/early-clinical synthetic biology company developing self-amplifying mRNA therapies for oncology. Comparable as a programmable RNA therapeutics peer focused on cancer immunotherapy with novel delivery approaches.
- Verve Therapeutics: Clinical-stage gene editing company using lipid nanoparticles to deliver in vivo CRISPR base editing to the liver for cardiovascular disease. Comparable as a peer using LNP delivery for nucleic acid-based therapeutics with focus on extrahepatic/tissue-specific delivery challenges that RNABL also targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Tiba Biotech social profiles
Digital presenceTiba Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tiba Biotech leadership team
Management profileNumber of profiles
Profiles6 records
Tiba Biotech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tiba Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tiba Biotech
What does Tiba Biotech do?
Tiba Biotech develops a proprietary biodegradable dendrimer nanoparticle delivery platform (RNABL) and a computational RNA design platform to create next-generation RNA vaccines and therapeutics for human and animal health. The company is pre-clinical and generates revenue through government grants and research partnerships rather than product sales, with a pipeline spanning pandemic influenza, betacoronaviruses, livestock diseases, and cancer immunotherapy.
Is Tiba Biotech a public or private company?
Tiba Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Tiba Biotech founded?
Tiba Biotech was founded in 2018. It employs 11 to 50 people.
Where is Tiba Biotech based?
Tiba Biotech is headquartered in Cambridge, United States, in the North America region.
How does Tiba Biotech make money?
Three revenue lines are on record. Government Grants and Contracts are the primary driver. The others are strategic Partnership Agreements and licensing Royalties (Future).
Who are Tiba Biotech's main competitors?
Broad incumbents on record are Moderna and BioNTech. Direct peers are CureVac, Arcturus Therapeutics, Translate Bio (acquired by Sanofi) and Replicate Bioscience. Others are Acuitas Therapeutics and Genevant Sciences. Emerging players are Strand Therapeutics and Verve Therapeutics.
Does Tiba Biotech have an API?
No public API is recorded for Tiba Biotech.
What industry is Tiba Biotech in?
Tiba Biotech's product category is RNA Therapeutics and Vaccines. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.